GENERATING TUMOR-SELECTIVE CONDITIONALLY ACTIVE BIOLOGIC ANTI-CTLA4 ANTIBODIES VIA PROTEIN-ASSOCIATED CHEMICAL SWITCHES
By Himalaya Therapeutics | News | January 19, 2021
Recent publication by our co-founder and chairman, Jay Short, that discussing the mechanism he developed that enables our product candidates to be conditionally active around cancer cells.
View LinkedIn post
© 2022 Himalaya Therapeutics. All rights reserved